Johnson & Johnson (NYSE: JNJ) delivered a solid Q1 performance, surpassing Wall Street expectations for both revenue and profit, as its pharmaceutical arm continues to shine — particularly in oncology. Despite some drag from biosimilar competition and U.S. tariffs, the company lifted its full-year revenue outlook, banking on its growing drug portfolio.
Q1 2025 Highlights
-
Revenue: $21.89 billion (+2.4% YoY)
-
Adjusted EPS: $2.77 (vs. $2.59 est.)
-
Innovative Medicines revenue: $13.87 billion (vs. $13.43 billion est.)
-
MedTech revenue: $8.02 billion (missed $8.17 billion est.)
Oncology Drives Growth
J&J’s cancer portfolio continues to power results:
-
Darzalex (multiple myeloma): $3.24 billion (+20% YoY)
-
Carvykti (cell therapy): $369 million (vs. $324 million est.)
-
Total oncology drug revenue: $5.68 billion (+18%)
These therapies not only beat expectations but signal strong demand resilience, especially for treatments with limited biosimilar threat.
Mixed Performance in Other Segments
-
Stelara (psoriasis): Down 33% to $1.63 billion — but still beat estimates of $1.42 billion
-
MedTech Division: Up 2.5% YoY, but short of expectations due to near-term softness (expected to improve H2 2025)
Guidance Update
-
FY Sales Guidance: Raised to $91.6B–$92.4B (from $90.9B–$91.7B)
-
Adjusted EPS Outlook: Lowered to $10.50–$10.70 (from $10.75–$10.95)
Why the EPS Cut?
-
$14.6B Intra-Cellular acquisition (maker of Caplyta for schizophrenia)
-
Impact of Trump-era tariffs
What to Watch
-
The biosimilar pressure on Stelara will likely intensify in the U.S.
-
Tariff policy shifts may weigh on future earnings
-
Integration of Intra-Cellular and the performance of Caplyta will be crucial in H2
For Deeper Analysis
Track JNJ’s valuation, profitability, and earnings trends using:
-
Financial Growth – Understand YoY and QoQ progress across key metrics
-
Full Financial as Reported – Get JNJ’s raw, audited numbers for a clear picture
Conclusion:
Johnson & Johnson’s solid Q1 beat and oncology momentum are positives, but margin pressures and biosimilar risk mean investors should keep expectations balanced. H2 execution in MedTech and Caplyta integration will be pivotal.
